References/Publications for Basophil/Mast cell_Histamine Test of Bet v 1

Check all              

Select PubMed ID Description
7573831 Allergy. 1995 May;50(5):421-30.

Isolation and characterization of the 18-kDa major apple allergen and comparison
with the major birch pollen allergen (Bet v I).

Vieths S(1), Janek K, Aulepp H, Petersen A.


8366100 J Biol Chem. 1993 Sep 15;268(26):19574-80.

Purification and characterization of recombinant Bet v I, the major birch pollen
allergen. Immunological equivalence to natural Bet v I.

Ferreira FD(1), Hoffmann-Sommergruber K, Breiteneder H, Pettenburger K, Ebner C,
Sommergruber W, Steiner R, Bohle B, Sperr WR, Valent P, et al.


8568143 J Allergy Clin Immunol. 1996 Jan;97(1 Pt 1):95-103.

Induction of IgE antibodies with predefined specificity in rhesus monkeys with
recombinant birch pollen allergens, Bet v 1 and Bet v 2.

Ferreira FD(1), Mayer P, Sperr WR, Valent P, Seiberler S, Ebner C, Liehl E,
Scheiner O, Kraft D, Valenta R.


8626988 J Allergy Clin Immunol. 1996 May;97(5):1100-9.

Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2:
diagnostic value for birch pollen and associated allergies.

Pauli G(1), Oster JP, Deviller P, Heiss S, Bessot JC, Susani M, Ferreira F, Kraft
D, Valenta R.


9058694 J Allergy Clin Immunol. 1997 Mar;99(3):374-84.

Immunologic characterization of monoclonal antibodies that modulate human IgE
binding to the major birch pollen allergen Bet v 1.

Lebecque S(1), Dolecek C, Laffer S, Visco V, Denépoux S, Pin JJ, Guret C,
Boltz-Nitulescu G, Weyer A, Valenta R.


9130536 Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):246-8.

Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic
fragments.

Vrtala S(1), Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR,
Valent P, Ebner C, Kraft D, Valenta R.


11421902 Allergy. 2001 Jun;56(6):548-52.

Diagnostic evaluation of grass- and birch-allergic patients with oral allergy
syndrome.

Anhoej C(1), Backer V, Nolte H.


11003446 Allergy. 2000 Sep;55(9):827-35.

Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II.
Side-effects.

Winther L(1), Malling HJ, Mosbech H.


15969669 Clin Exp Allergy. 2005 Jun;35(6):774-81.

Development of an in vitro system for the study of allergens and
allergen-specific immunoglobulin E and immunoglobulin G: Fcepsilon receptor I
supercross-linking is a possible new mechanism of immunoglobulin G-dependent
enhancement of type I allergic reactions.

Sellge G(1), Laffer S, Mierke C, Vrtala S, Hoffmann MW, Klempnauer J, Manns MP,
Valenta R, Bischoff SC.


15722633 Int Arch Allergy Immunol. 2005 Mar;136(3):239-49. Epub 2005 Feb 16.

Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against
birch pollen allergy.

Batard T(1), Didierlaurent A, Chabre H, Mothes N, Bussičres L, Bohle B, Couret
MN, Ball T, Lemoine P, Focks Tejkl M, Chenal A, Clément G, Dupont F, Valent P,
Krauth MT, André C, Valenta R, Moingeon P.


15722633 Int Arch Allergy Immunol. 2005 Mar;136(3):239-49. Epub 2005 Feb 16.

Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against
birch pollen allergy.

Batard T(1), Didierlaurent A, Chabre H, Mothes N, Bussičres L, Bohle B, Couret
MN, Ball T, Lemoine P, Focks Tejkl M, Chenal A, Clément G, Dupont F, Valent P,
Krauth MT, André C, Valenta R, Moingeon P.


17889932 J Allergy Clin Immunol. 2008 Jan;121(1):246-52. Epub 2007 Sep 24.

Naturally occurring hypoallergenic Bet v 1 isoforms fail to induce IgE responses
in individuals with birch pollen allergy.

Wagner S(1), Radauer C, Bublin M, Hoffmann-Sommergruber K, Kopp T, Greisenegger
EK, Vogel L, Vieths S, Scheiner O, Breiteneder H.


17912007 Int Arch Allergy Immunol. 2008;145(3):193-206. Epub 2007 Oct 2.

Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate
for allergen-specific immunotherapy.

Kahlert H(1), Suck R, Weber B, Nandy A, Wald M, Keller W, Cromwell O, Fiebig H.


18241932 Immunol Lett. 2008 Apr 15;117(1):50-6. doi: 10.1016/j.imlet.2007.11.025. Epub
2007 Dec 31.

Susceptibility to nasal and oral tolerance induction to the major birch pollen
allergen Bet v 1 is not dependent on the presence of the microflora.

Repa A(1), Kozakova H, Hudcovic T, Stepankova R, Hrncir T, Tlaskalova-Hogenova H,
Pollak A, Wiedermann U.


19183416 Allergy. 2009 Jul;64(7):1038-45. doi: 10.1111/j.1398-9995.2009.01957.x. Epub 2009
Jan 31.

Standardization of allergen products: 1. Detailed characterization of
GMP-produced recombinant Bet v 1.0101 as biological reference preparation.

Himly M(1), Nony E, Chabre H, Van Overtvelt L, Neubauer A, van Ree R, Buchheit
KH, Vieths S, Moingeon P, Ferreira F.


19274924 J Investig Allergol Clin Immunol. 2009;19(1):13-20.

Component-resolved in vitro diagnosis in peach-allergic patients.

Gamboa PM(1), Sanz ML, Lombardero M, Barber D, Sánchez-Monje R, Goikoetxea MJ,
Antépara I, Ferrer M, Salcedo G.


21093057 Mol Immunol. 2011 Jan;48(4):431-41. doi: 10.1016/j.molimm.2010.09.016. Epub 2010
Nov 18.

Altered IgE epitope presentation: A model for hypoallergenic activity revealed
for Bet v 1 trimer.

Campana R(1), Vrtala S, Maderegger B, Dall'Antonia Y, Zafred D, Blatt K, Herrmann
H, Focke-Tejkl M, Swoboda I, Scheiblhofer S, Gieras A, Neubauer A, Keller W,
Valent P, Thalhamer J, Spitzauer S, Valenta R.


21451110 J Immunol. 2011 May 1;186(9):5333-44. doi: 10.4049/jimmunol.1000804. Epub 2011
Mar 30.

Mapping of conformational IgE epitopes with peptide-specific monoclonal
antibodies reveals simultaneous binding of different IgE antibodies to a surface
patch on the major birch pollen allergen, Bet v 1.

Gieras A(1), Cejka P, Blatt K, Focke-Tejkl M, Linhart B, Flicker S, Stoecklinger
A, Marth K, Drescher A, Thalhamer J, Valent P, Majdic O, Valenta R.


23844022 PLoS One. 2013 Jul 2;8(7):e67544. doi: 10.1371/journal.pone.0067544. Print 2013.

Oesophagostomum dentatum extract modulates T cell-dependent immune responses to
bystander antigens and prevents the development of allergy in mice.

Schabussova I(1), Ul-Haq O, Hoflehner E, Akgün J, Wagner A, Loupal G, Joachim A,
Ruttkowski B, Maizels RM, Wiedermann U.


--DOI:10.1186/2045-7022-3-S3-O15
26042900 PLoS One. 2015 Jun 4;10(6):e0128677. doi: 10.1371/journal.pone.0128677.
eCollection 2015.

Ligand Recognition of the Major Birch Pollen Allergen Bet v 1 is Isoform
Dependent.

Seutter von Loetzen C(1), Jacob T(1), Hartl-Spiegelhauer O(1), Vogel L(2),
Schiller D(2), Spörlein-Güttler C(3), Schobert R(3), Vieths S(2), Hartl MJ(1),
Rösch P(1).


27770477 Clin Exp Allergy. 2017 May;47(5):693-703. doi: 10.1111/cea.12835. Epub 2016 Nov


IgE and allergen-specific immunotherapy-induced IgG4 recognize similar epitopes
of Bet v 1, the major allergen of birch pollen.

Groh N(1), von Loetzen CS(2), Subbarayal B(3), Möbs C(4), Vogel L(1), Hoffmann
A(1), Fötisch K(1), Koutsouridou A(1), Randow S(1), Völker E(1), Seutter von
Loetzen A(1), Rösch P(2), Vieths S(1), Pfützner W(4), Bohle B(3), Schiller D(1).


28070926 Mol Nutr Food Res. 2017 Apr;61(4). doi: 10.1002/mnfr.201600902. Epub 2017 Feb 10.

Identification and implication of an allergenic PR-10 protein from walnut in
birch pollen associated walnut allergy.

Wangorsch A(1), Jamin A(1), Lidholm J(2), Gräni N(3), Lang C(3), Ballmer-Weber
B(3)(4), Vieths S(1), Scheurer S(1).


28456624 J Allergy Clin Immunol. 2018 Jan;141(1):293-299.e6. doi:
1016/j.jaci.2017.02.044. Epub 2017 Apr 26.

Fusion proteins of flagellin and the major birch pollen allergen Bet v 1 show
enhanced immunogenicity, reduced allergenicity, and intrinsic adjuvanticity.

Kitzmüller C(1), Kalser J(1), Mutschlechner S(1), Hauser M(2), Zlabinger GJ(3),
Ferreira F(2), Bohle B(4).


29065418 Int Arch Allergy Immunol. 2017;174(2):77-85. doi: 10.1159/000481092. Epub 2017
Oct 25.

Characterization of a Major Allergen from Mongolian Oak, Quercus mongolica, a
Dominant Species of Oak in Korea.

Lee JY(1), Yang M, Jeong KY, Sim DW, Park JH, Park KH, Lee JH, Park JW.


29885257 Allergy. 2018 Oct;73(10):2080-2082. doi: 10.1111/all.13498. Epub 2018 Jul 2.

Major hazelnut and peanut allergens are potent in basophil activation and
cross-react at T-cell level.

Masthoff LJN(1), Pasmans SGMA(1), van Doorn H(1), den Hartog Jager CF(1),
Geneugelijk K(1), Knol EF(1)(2), Bruijnzeel-Koomen CAFM(1), Lidholm J(3), Knulst
AC(1), Hoffen E(1).


29940558 Int Arch Allergy Immunol. 2018;177(2):116-122. doi: 10.1159/000489707. Epub 2018
Jun 25.

Harmonization of the Genetic Code Effectively Enhances the Recombinant Production
of the Major Birch Pollen Allergen Bet v 1.

Asam C(1), Roulias A(1), Parigiani MA(1), Haab A(1), Wallner M(1), Wolf M(1),
Briza P(1), Bohle B(2), Ferreira F(1), Hauser M(1).


30706562 Clin Exp Allergy. 2019 May;49(5):712-723. doi: 10.1111/cea.13356. Epub 2019 Feb


Quality and potency profile of eight recombinant isoallergens, largely mimicking
total Bet v 1-specific IgE binding of birch pollen.

Seutter von Loetzen C(1), Reuter A(2), Spiric J(2), Schulenborg T(2),
Bellinghausen I(3), Völker E(2), Vogel L(2), Rösch P(1), Schiller D(2).


30850635 Sci Rep. 2019 Mar 8;9(1):4006. doi: 10.1038/s41598-019-39798-8.

Fusion proteins consisting of Bet v 1 and Phl p 5 form IgE-reactive aggregates
with reduced allergenic activity.

Najafi N(1), Hofer G(2), Gattinger P(1), Smiljkovic D(3), Blatt K(3), Selb R(4),
Stoecklinger A(5), Keller W(2), Valent P(3), Niederberger V(4), Thalhamer J(5),
Valenta R(1)(6)(7), Flicker S(8).


32784509 Int J Mol Sci. 2020 Aug 8;21(16). pii: E5693. doi: 10.3390/ijms21165693.

Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG1 and IgG4
against the Major Birch Pollen Allergen Bet v 1.

Köhler VK(1)(2), Crescioli S(3)(4), Fazekas-Singer J(1)(2), Bax HJ(3)(5), Hofer
G(6), Pranger CL(1)(2), Hufnagl K(1)(2), Bianchini R(1)(2), Flicker S(2), Keller
W(6), Karagiannis SN(3)(4)(7), Jensen-Jarolim E(1)(2).


33724487 Allergy. 2021 Aug;76(8):2555-2564. doi: 10.1111/all.14817. Epub 2021 May 6.

IgE-cross-blocking antibodies to Fagales following sublingual immunotherapy with
recombinant Bet v 1.

Grilo JR(1), Kitzmüller C(1), Aglas L(2), Sánchez Acosta G(1), Vollmann U(1),
Ebner C(3), Horak F(4), Kinaciyan T(5), Radauer C(1), Ferreira F(2), Jahn-Schmid
B(1), Bohle B(1).


34126155 J Allergy Clin Immunol. 2022 Jan;149(1):200-211. doi: 10.1016/j.jaci.2021.05.038.
Epub 2021 Jun 11.

Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the
birch allergic response.

Atanasio A(1), Franklin MC(1), Kamat V(1), Hernandez AR(1), Badithe A(1), Ben
LH(1), Jones J(1), Bautista J(1), Yancopoulos GD(1), Olson W(1), Murphy AJ(1),
Sleeman MA(1), Orengo JM(2).


34126156 J Allergy Clin Immunol. 2022 Jan;149(1):189-199. doi: 10.1016/j.jaci.2021.05.039.
Epub 2021 Jun 11.

Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch
allergy symptoms in a phase 1 study.

Gevaert P(1), De Craemer J(1), De Ruyck N(1), Rottey S(2), de Hoon J(3), Hellings
PW(4), Volckaert B(5), Lesneuck K(5), Orengo JM(6), Atanasio A(6), Kamal MA(6),
Abdallah H(6), Kamat V(6), Dingman R(6), DeVeaux M(6), Ramesh D(6), Perlee L(6),
Wang CQ(6), Weinreich DM(6), Herman G(6), Yancopoulos GD(6), O'Brien MP(7).


34837242 Allergy. 2021 Nov 27. doi: 10.1111/all.15191. [Epub ahead of print]

Isolation of nanobodies with potential to reduce patients' IgE binding to Bet v


Zettl I(1), Ivanova T(2), Strobl MR(3), Weichwald C(1), Goryainova O(2), Khan
E(2), Rutovskaya MV(2)(4), Focke-Tejkl M(1), Drescher A(5), Bohle B(3), Flicker
S(1), Tillib SV(2).